Dr. Matthew Daniel Lippas, MD

Dr. Lippas practices at Sweeney Eye Associates in Richardson, Texas.

Dr. Lippas' NPI, 1790770717, was assigned on September 15, 2005. Dr. Lippas graduated from McGovern Medical School in 1983. Dr. Lippas holds Texas license G6740.

Dr. Lippas' primary practice is Sweeney Eye Associates, at 3609 Shire Blvd, Richardson, TX 75082 in Dallas County. The practice phone is (972) 285-8966.

Dr. Lippas' primary practice is Sweeney Eye Associates in Richardson, Texas. Dmand AI also links Dr. Lippas to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lippas practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Lippas' primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Lippas is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Lippas' licenses on file in 5 states: Texas, Tennessee, Alabama, Arkansas and Washington.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Lippas treats.

CMS data shows 9,568 Medicare services from Dr. Lippas across 12 procedure codes in 2024, for 333 Medicare patients. Medicare paid $420,019 for them. Every service was in an office.

CMS counts 333 Medicare patients who saw Dr. Lippas in 2024. The largest group is 65 to 74, with 145 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lippas' median patient age at 71, with 55% women.

In 2024, Dr. Lippas wrote 528 Medicare Part D claims for 183 patients. 64% of them were for generic drugs. CMS names the drug for 457 of them, across 13 drugs with 11 or more claims each, at $25,027 in total drug cost. In 2023, CMS named 514 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Lippas for performance year 2024, reported as part of a group. Dr. Lippas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 47 general payments to Dr. Lippas from 17 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 89% of the total. Abbvie Inc. paid the most, $267. It also lists 1 research payment totaling $350 in 2017.

Dr. Lippas graduated from McGovern Medical School in 1983.

Dr. Lippas is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.